Nutter Intellectual Property Team Advises Abcuro, Inc.; Abcuro Recently Closed $42 Million Series A-1 FinancingPrint PDF
Nutter is pleased that its client Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, recently closed a $42 million Series A-1 financing. Nutter provides legal counsel to Abcuro related to their expanding patent portfolio. The Nutter team is led by Kathy Williams, Ph.D., a partner in Nutter’s Intellectual Property Department and the co-chair of the firm’s Life Sciences practice group, and includes Amy DeCloux, Ph.D., Gurunathan Laxmikanthan, Ph.D., and Rory P. Pheiffer.
The financing was co-led by Mass General Brigham Ventures and Sanofi Ventures, and included investors Pontifax Venture Capital, Hongsen Investment Group, RA Capital Management, and Samsara BioCapital, as well as others. Proceeds from this financing will be used to advance ABC008, an anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy tissue in a variety of autoimmune diseases. A first-in-human proof of mechanism and safety trial will be conducted in patients with sporadic inclusion body myositis (IBM) while additional indications are under investigation. IBM is a chronic and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. The Series A-1 proceeds will also support ongoing preclinical development of the company’s oncology program ABC015, an anti-KLRG1 blocking antibody capable of restoring effector cytotoxic T and NK cell function, resulting in a potent anti-tumor response. This includes financial and scientific support by the Multiple Myeloma Research Foundation to assess ABC015 in multiple myeloma. More information on the transaction.
Nutter’s Intellectual Property Department advises clients on a broad array of issues, including patent portfolio development, counseling, and prosecution; IP due diligence; litigation; trademarks, copyrights, and trade secrets; technology licensing; international IP rights; opinions of counsel; and more. Nutter attorneys help clients to unlock the value of their IP, creating revenue streams from licensing and sales. Global corporations, mid-market and emerging companies, major universities and research institutions, inventors, investors, and entrepreneurs turn to Nutter’s team for a wide variety of IP matters. Nutter is recognized in Best Lawyers in America 2021 for Patent Law.
Nutter is a Boston-based law firm that provides legal counsel to industry-leading companies, early stage entrepreneurs, institutions, foundations, and families, across the country and around the world. The firm’s business and finance, intellectual property, litigation, real estate and land use, labor and employment, tax, and trusts and estates practices are national in scope. The firm was co-founded in 1879 by former U.S. Supreme Court Justice Louis D. Brandeis, before his appointment to the Court. For more information, please visit www.nutter.com and follow the firm on LinkedIn.